Clinical Trial Update: Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update reporting a completed Phase 2/Phase 3 study of pexacerfont (BMS-562086) in outpatients with generalized anxiety disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Anxiety Disorder

Drugs mentioned

• Pexacerfont (pexacerfont)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Generalized Anxiety Disorder | Phase 2, Phase 3 | Status: COMPLETED